MEDTEQ+ AVISÉ Program

Insider Tip

The gate that stops most applicants is not the score, it is the matchmaking. MEDTEQ+ requires you to be accompanied by an innovation integration officer and matched with a willing RÉIS evaluation team before a submission is even accepted, and the evaluation team co-designs the study and prices its own service offer as part of your application. That process runs on relationship time, not deadline time — so contact [email protected] whether or not a call is open. Two other things catch people out. Expenses incurred before the final submission deadline are not eligible, including anything you have already contractually committed to, so do not start the study early. And if your technology has already won a public tender or been commercialized anywhere, it is ineligible outright — this program funds evidence for products that have not yet had a first sale.

Rejection Pitfalls 8

• The technology is already commercialized or has won a tender or contract — explicitly ineligible
• TRL outside the 7-9 pre-commercialization band
• No RÉIS evaluation team willing to take on the project

Success Profile

A Quebec-registered medtech, digital-health or health-AI company that owns its IP, has at least one founder working on it full-time, and has a technology at TRL 7-9 that has never been sold under a tender or commercialized — with a determinant advantage over the current standard, ideally answering one of the four published priority needs, and with at least 25% of the project cost available in private funding. The strongest candidates start the RÉIS matchmaking conversation long before a deadline exists.

Evaluation Criteria

Scored out of 100 on five criteria. Innovative character of the technology (25): a determinant advantage of the product or process over existing market solutions nationally or internationally. Overall value of the innovation and social acceptability (25): potential impacts at the population, clinical, organizational, sociocultural and environmental levels, whether the project answers one of the call's priority needs, and social acceptability. Feasibility and relevance of the project against the call's objectives (25): quality and realism of the implementation plan including schedule and budget, quality of non-RÉIS partners and their service offers, management of risk and uncertainty, sustainable-development elements, and relevance to the technology's development. Capacity of the company to deliver (15): coherence with business strategy, track record of projects and milestones achieved, and internal technical, clinical, regulatory and commercial capability. Potential returns for the company and its sector (10): market assessment, business and go-to-market model, prior commercialization experience, and the strength of the intellectual-property position and strategy. Each criterion needs a minimum of 50%, except innovative character which has an 80% eliminatory threshold (20 of 25), and a project is only admissible at a minimum overall score of 80 out of 100 — which still does not guarantee funding.

Application Steps

Required Documents 10

Eligible Expenses 14

• Direct labour costs for personnel assigned to the project, including social benefits and mandatory plan contributions
• Scholarships for students
• Materials, consumables and supplies
• Purchase or rental of equipment — capped at 25% of total eligible expenses
• Travel and accommodation related to the project, per Quebec government standards
• Professional fees for the evaluation of the technology by the evaluation expert
• Professional fees for implementing and using the technology in the evaluation setting(s)
• Professional fees, specialized services and subcontracting
• Costs of disseminating results
• Specialized platform fees
• Acquisition of studies or other documentation
• Monetary compensation for participants
• MEDTEQ+ project management fees — financial plans must provision 5% of the budget for MEDTEQ+'s management and monitoring
• Indirect research costs (FIR)

Ineligible Expenses 9

• Any expense incurred before the final submission deadline, including expenses the business has already contractually committed to
• Ordinary operating expenses of the business
• Goods and services taxes applicable in Quebec
• Recurring costs such as annual subscription fees and software update fees
• Capital expenditure and depreciation
• Sponsorships
• Debt service, repayment of future borrowings, capital losses or capital replacement, and any payment made as capital
• Intellectual property maintenance and commercialization expenses
• Equipment purchase or rental above 25% of total eligible expenses

Intake Periods

The call for projects launched June 5, 2025 with an online information session on June 17, 2025, and offered exactly three submission opportunities: deposit 1 closed September 8, 2025 (decisions November 2025), deposit 2 closed December 1, 2025 (decisions March 2026), and deposit 3 — the last — closed April 17, 2026 after a March 13, 2026 pre-submission checkpoint, with the evaluation committee meeting May 28, 2026 and decisions in June 2026. No fourth deposit and no new call have been published. Contact [email protected] to be in the queue if one opens.

Deadline Notes

The call for projects launched June 5, 2025 with exactly three submission opportunities, and the third and last one closed April 17, 2026 (pre-submission March 13, 2026). MEDTEQ+ has not published a fourth deposit or a new call, so there is no date to plan against right now — the program page still carries 'new call for projects' language from the original launch. If AVISÉ interests you, the useful move is not to wait for a date: MEDTEQ+ requires every applicant to be accompanied by an innovation integration officer and matched with a RÉIS evaluation team before a submission is even accepted, and that matchmaking takes months. Contact [email protected] now and be in the queue if a further call opens.

Ineligible Organizations

• Businesses listed, provisionally or definitively, on Quebec's Registre des entreprises non admissibles aux contrats publics (RENA) — this also applies to RENA-listed subcontractors expected to work on the project
• Businesses on the Office québécois de la langue française list of enterprises non-compliant with the francization process
• Businesses that, in the two years before the application, failed to meet their obligations after formal notice in connection with previous financial aid from a Quebec government department or agency
• Crown corporations, entities controlled directly or indirectly by a municipal, provincial or federal government, municipal entities, and businesses majority-owned by a Crown corporation
• Businesses under the protection of the Companies' Creditors Arrangement Act or the Bankruptcy and Insolvency Act
• Holding companies
• Businesses whose main line of business is weapons production or distribution
• Businesses whose main line of business is fossil-fuel exploration, extraction, drilling, production or refining — except activities aimed at a low-carbon transition
• Businesses whose main line of business is gambling, including casinos, bingo halls and gaming terminals
• Businesses whose main line of business is violent games, combat sports involving any living species, racing or similar activities
• Businesses whose main line of business is sexual exploitation, including erotic bars, escort agencies, erotic massage parlours, swingers clubs or pornographic material production
• Businesses whose main line of business is the production, sale or servicing of tobacco or drug consumption

Stacking partner data not yet available.

Clawback Risk

MEDTEQ+ explicitly reserves the right to withdraw all or part of the allocation already paid if the company or its partner fails to meet the obligations set out in the grant agreement, or if the money was used for other purposes. Because 25% is paid as an advance before any expenses are reimbursed, that is a genuine repayment exposure rather than only a stop on future tranches. MEDTEQ+ also reserves the right to reduce the first payment based on its analysis of your financial statements, and may require an external auditor's report before releasing later tranches.